Pipeline Review for Rubella (German Measles): H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Rubella (German Measles) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Discovery and Unknown stages are 4, 1, 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Companies Mentioned

  • Biological E Ltd
  • Cadila Healthcare Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Sinovac Biotech Ltd

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Rubella (German Measles) - Overview
  4. Rubella (German Measles) - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Rubella (German Measles) - Therapeutics Assessment
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Rubella (German Measles) - Companies Involved in Therapeutics Development
  14. Biological E Ltd
  15. Cadila Healthcare Ltd
  16. GlaxoSmithKline Plc
  17. Indian Immunologicals Ltd
  18. Sinovac Biotech Ltd
  19. Rubella (German Measles) - Drug Profiles

For more information about this report visit https://www.researchandmarkets.com/research/wkz5gx/pipeline_review?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs